{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:51:12Z","timestamp":1792803072364,"version":"4.5.0"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pharmthera.2026.109089","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:34:51Z","timestamp":1784853291000},"page":"109089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring"],"prefix":"10.1016","volume":"286","author":[{"given":"Yafeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keman","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bib885","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in Type 2 diabetes: A mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109089_bb0005","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2026.109089_bb0010","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"7814","key":"10.1016\/j.pharmthera.2026.109089_bib891","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bb0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.538132","article-title":"Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham heart study","volume":"112","author":"Arnl\u00f6v","year":"2005","journal-title":"Circulation"},{"issue":"10201","key":"10.1016\/j.pharmthera.2026.109089_bb0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0140-6736(19)31721-0","article-title":"An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outcome prediction","volume":"394","author":"Attia","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109089_bib884","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0025","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1681\/ASN.2014010108","article-title":"High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: The chronic renal insufficiency cohort (CRIC) study","volume":"26","author":"Bansal","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10875-011-9622-7","article-title":"Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease","volume":"32","author":"Bao","year":"2012","journal-title":"Journal of Clinical Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/CIRCULATIONAHA.121.057852","article-title":"Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with Reduced ejection fraction: An analysis of the DAPA-HF Trial","volume":"145","author":"Berg","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7326\/L17-0589","article-title":"Racial differences in the relationship of glucose concentrations and Hemoglobin A1c levels","volume":"168","author":"Bergenstal","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bib876","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"30","key":"10.1016\/j.pharmthera.2026.109089_bb0055","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/eurheartj\/ehw172","article-title":"Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium","volume":"37","author":"Blankenberg","year":"2016","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3803\/EnM.2017.32.1.47","article-title":"The implication of coronary artery calcium testing for cardiovascular disease Prevention and diabetes","volume":"32","author":"Blankstein","year":"2017","journal-title":"Endocrinology and Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0065","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: A novel mediator of heart failure development and progression","volume":"11","author":"de Boer","year":"2009","journal-title":"European Journal of Heart Failure"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bib886","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109089_bb0070","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized Trial of Interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"6865","key":"10.1016\/j.pharmthera.2026.109089_bb0075","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ehf2.12235","article-title":"Low NT-proBNP levels in overweight and obese patients do not Rule out a diagnosis of heart failure with preserved ejection fraction","volume":"5","author":"Buckley","year":"2018","journal-title":"ESC Heart Failure"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109089_bb0085","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jacc.2006.10.079","article-title":"Long-term prognosis associated with coronary calcification: Observations from a registry of 25,253 patients","volume":"49","author":"Budoff","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/03009734.2019.1696430","article-title":"Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: A proteomics approach","volume":"125","author":"Carlsson","year":"2020","journal-title":"Upsala Journal of Medical Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109089_bb0095","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0100","article-title":"Prognostic value of serum Galectin-3 in chronic heart failure: A meta-analysis","volume":"9","author":"Cheng","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31083\/j.rcm.2020.02.17","article-title":"High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond","volume":"21","author":"Chuang","year":"2020","journal-title":"Reviews in Cardiovascular Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: A state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"issue":"7795","key":"10.1016\/j.pharmthera.2026.109089_bb0115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109089_bb0120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in Normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109089_bb0135","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/ajkd.2002.34487","article-title":"Serum cystatin C is superior to serum creatinine as a marker of kidney function: A Meta-analysis","volume":"40","author":"Dharnidharka","year":"2002","journal-title":"American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bib887","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCC.0b013e32833e2fa4","article-title":"Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care","volume":"16","author":"Doi","year":"2010","journal-title":"Current Opinion in Critical Care"},{"issue":"9493","key":"10.1016\/j.pharmthera.2026.109089_bb0145","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical Trial in macroVascular events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109089_bb0150","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2215\/CJN.10881016","article-title":"Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on Hemodialysis","volume":"12","author":"Drechsler","year":"2017","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0155","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/ATVBAHA.120.315452","article-title":"Trained immunity and reactivity of macrophages and endothelial cells","volume":"41","author":"Drummer","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/2050-7771-1-17","article-title":"Metabolomic analyses for atherosclerosis, diabetes, and obesity","volume":"1","author":"Du","year":"2013","journal-title":"Biomarker Research"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6151847","article-title":"Trametenolic acid ameliorates the progression of diabetic nephropathy in Db\/Db mice via Nrf2\/HO-1 and NF-\u03baB-mediated pathways","volume":"2022","author":"Duan","year":"2022","journal-title":"Journal of Immunology Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bib880","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: A review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1681\/ASN.2015010074","article-title":"Extracellular vesicles in renal diseases: More than novel biomarkers?","volume":"27","author":"Erdbr\u00fcgger","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts Cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"Journal of Internal Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bb0185","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1415921","article-title":"Troponin and cardiac events in stable ischemic heart disease and diabetes","volume":"373","author":"Everett","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109089_bb0190","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and Reduced ejection fraction: A randomized clinical Trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bib898","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME trial: A \u201cThrifty Substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0200","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annual Review of Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0205","first-page":"72","volume":"72","author":"Fourth universal definition of myocardial infarction","year":"2018","journal-title":"2019. Revista Espa\u00f1ola de Cardiolog\u00eda"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0210","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","article-title":"Inflammaging: A new immune-metabolic viewpoint for age-related diseases","volume":"14","author":"Franceschi","year":"2018","journal-title":"Nature Reviews. Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/21623945.2017.1402151","article-title":"Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk","volume":"7","author":"Fr\u00fchbeck","year":"2018","journal-title":"Adipocyte"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bib888","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1753-0407.2009.00009.x","article-title":"Review of hemoglobin A(1c) in the management of diabetes","volume":"1","author":"Gallagher","year":"2009","journal-title":"Journal of Diabetes"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0220","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41588-024-01898-1","article-title":"Disease prediction with multi-omics and biomarkers empowers case-control genetic discoveries in the UK biobank","volume":"56","author":"Garg","year":"2024","journal-title":"Nature Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bib890","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.metabol.2011.09.009","article-title":"The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort","volume":"61","author":"Gasevic","year":"2012","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052036","article-title":"Insulin resistance and risk of incident cardiovascular events in adults without diabetes: Meta-analysis","volume":"7","author":"Gast","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109089_bb0235","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure: Biological and translational perspectives","volume":"71","author":"Gonz\u00e1lez","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0240","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40292-022-00542-5","article-title":"HOMA-IR as a predictor of health outcomes in patients with metabolic risk factors: A systematic review and meta-analysis","volume":"29","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2022","journal-title":"High Blood Pressure & Cardiovascular Prevention: The Official Journal of the Italian Society of Hypertension"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109089_bb0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6101(99)00037-4","article-title":"TGF-Beta in blood: A complex problem","volume":"11","author":"Grainger","year":"2000","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109089_bb0250","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer Cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109089_bb0255","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bb0260","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jchf.2015.02.008","article-title":"Racial differences in natriuretic peptide levels: The Dallas heart study","volume":"3","author":"Gupta","year":"2015","journal-title":"JACC. Heart Failure"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0265","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2009.07.020","article-title":"Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-analysis","volume":"54","author":"Haase","year":"2009","journal-title":"American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0270","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: Mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nature Reviews. Nephrology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bb0275","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly Efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"The Lancet. Gastroenterology & Hepatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bb0280","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a Trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nature Medicine"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109089_bb0285","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109089_bib895","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bib882","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109089_bb0290","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/heartjnl-2020-318860","article-title":"Addition of cystatin C predicts cardiovascular death better than creatinine in intensive care","volume":"108","author":"Helmersson-Karlqvist","year":"2022","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0300","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.ATV.0000193567.88685.f4","article-title":"Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction","volume":"26","author":"Hemdahl","year":"2006","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","article-title":"New insights into TGF-\u03b2\/Smad Signaling in tissue fibrosis","volume":"292","author":"Hu","year":"2018","journal-title":"Chemico-Biological Interactions"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109089_bb0315","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0325","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1161\/CIRCRESAHA.117.310752","article-title":"Extracellular vesicles in cardiovascular disease: Potential applications in diagnosis, prognosis, and epidemiology","volume":"120","author":"Jansen","year":"2017","journal-title":"Circulation Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bb0330","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109089_bb0335","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0340","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/nyas.12758","article-title":"MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets","volume":"1353","author":"Kato","year":"2015","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.962561","article-title":"Multi-organ FGF21-FGFR1 Signaling in metabolic health and disease","volume":"9","author":"Kaur","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109089_bib894","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","article-title":"Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure","volume":"50","author":"Kempf","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0350","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0355","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2005.04.051","article-title":"Race and gender differences in C-reactive protein levels","volume":"46","author":"Khera","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0360","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.metabol.2009.07.027","article-title":"Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?","volume":"59","author":"Kim-Dorner","year":"2010","journal-title":"Metabolism, Clinical and Experimental"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109089_bb0365","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f1654","article-title":"Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: Systematic review and Meta-analysis","volume":"346","author":"Kramer","year":"2013","journal-title":"BMJ"},{"issue":"39","key":"10.1016\/j.pharmthera.2026.109089_bib878","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0375","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cardfail.2021.10.006","article-title":"Sex differences in heart failure","volume":"28","author":"Lala","year":"2022","journal-title":"Journal of Cardiac Failure"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0380","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/1354750X.2011.555822","article-title":"Cystatin C, NT-proBNP, and inflammatory markers in acute heart failure: Insights into the cardiorenal syndrome","volume":"16","author":"Lassus","year":"2011","journal-title":"Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bib893","first-page":"50","article-title":"Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33\/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction","volume":"3","author":"Lax","year":"2015","journal-title":"JACC: Heart Failure"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0385","doi-asserted-by":"crossref","first-page":"573","DOI":"10.18632\/aging.101414","article-title":"An epigenetic biomarker of aging for lifespan and Healthspan","volume":"10","author":"Levine","year":"2018","journal-title":"Aging"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0390","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2337\/dc08-1596","article-title":"Plasma leptin levels and incidence of heart failure, cardiovascular disease, and Total mortality in elderly individuals","volume":"32","author":"Lieb","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109089_bb0395","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled Trial of the FGF21 analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"11\u221212","key":"10.1016\/j.pharmthera.2026.109089_bb0400","article-title":"The omics-driven machine learning path to Cost-effective precision medicine in chronic kidney disease","volume":"25","author":"Lopes","year":"2025","journal-title":"Proteomics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0405","doi-asserted-by":"crossref","first-page":"303","DOI":"10.18632\/aging.101684","article-title":"DNA methylation GrimAge strongly predicts lifespan and Healthspan","volume":"11","author":"Lu","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0410","article-title":"Aorta in pathologies may function as an immune organ by upregulating secretomes for immune and vascular cell activation, differentiation and trans-differentiation-early secretomes may serve as drivers for trained immunity","volume":"13","author":"Lu","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0415","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":"Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure","volume":"176","author":"Madamanchi","year":"2014","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cca.2022.08.029","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury - A systematic review","volume":"536","author":"Marakala","year":"2022","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109089_bb0425","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and Beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0430","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.amjmed.2019.05.047","article-title":"Relation of kidney function decline and NT-proBNP with risk of mortality and readmission in acute decompensated heart failure","volume":"133","author":"McCallum","year":"2020","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0435","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ijcard.2015.03.436","article-title":"Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The atherosclerosis risk in communities cohort study","volume":"187","author":"McEvoy","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109089_bb0440","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0445","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: The master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nature Reviews. Nephrology"},{"issue":"40","key":"10.1016\/j.pharmthera.2026.109089_bb0450","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF Trial","volume":"40","author":"Morrow","year":"2019","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0455","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart failure association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0460","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cca.2016.10.034","article-title":"Diagnostic and prognostic accuracy of Galectin-3 and soluble ST2 for acute heart failure","volume":"463","author":"Mueller","year":"2016","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0465","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/nm.4392","article-title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman Primates","volume":"23","author":"Mullican","year":"2017","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bib892","article-title":"Association between angiotensin receptor\u2013neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction","volume":"14","author":"Murphy","year":"2021","journal-title":"Circulation: Heart Failure"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109089_bb0470","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: The PARADIGM-HF Trial","volume":"73","author":"Myhre","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109089_bb0475","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109089_bb0480","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0485","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bib881","first-page":"489","article-title":"Practical guidance in echocardiographic assessment of global longitudinal strain","volume":"8","author":"Negishi","year":"2015","journal-title":"JACC: Cardiovascular Imaging"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0490","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral Muvalaplin for lowering of lipoprotein(a): A randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0495","doi-asserted-by":"crossref","unstructured":"Nidorf, Stefan M., Aernoud T. L. Fiolet, Arend Mosterd, John W. Eikelboom, Astrid Schut, Tjerk S. J. Opstal, Salem H. K. The, Xiao-Fang Xu, Mark A. Ireland, Timo Lenderink, Donald Latchem, Pieter Hoogslag, Anastazia Jerzewski, Peter Nierop, Alan Whelan, Randall Hendriks, Henk Swart, Jeroen Schaap, Aaf F. M. Kuijper, Maarten W. J. van Hessen, Pradyot Saklani, Isabel Tan, Angus G. Thompson, Allison Morton, Chris Judkins, Willem A. Bax, Maurits Dirksen, Marco Alings, Graeme J. Hankey, Charley A. Budgeon, Jan G. P. Tijssen, Jan H. Cornel, Peter L. Thompson, and LoDoCo2 Trial Investigators. 2020. \u201cColchicine in patients with chronic coronary disease.\u201d New England Journal of Medicine 383(19):1838\u201347. doi:https:\/\/doi.org\/10.1056\/NEJMoa2021372.","DOI":"10.1056\/NEJMoa2021372"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109089_bb0500","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): A randomized dose-ascending clinical Trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109089_bb0505","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120414","article-title":"Multiomics in atherosclerotic cardiovascular disease","volume":"408","author":"Nordestgaard","year":"2025","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109089_bb0515","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s00125-018-4641-z","article-title":"Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes","volume":"61","author":"Nowak","year":"2018","journal-title":"Diabetologia"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109089_bb0520","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"7477","key":"10.1016\/j.pharmthera.2026.109089_bb0525","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature12656","article-title":"A Small-molecule AdipoR agonist for type 2 diabetes and short life in obesity","volume":"503","author":"Okada-Iwabu","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0530","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41588-023-01625-2","article-title":"Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK biobank","volume":"56","author":"Oliveri","year":"2024","journal-title":"Nature Genetics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0535","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nature Reviews. Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bib897","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109089_bb0540","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0545","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ejhf.2256","article-title":"Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a Reduced ejection fraction and the influence of empagliflozin: The EMPEROR-Reduced Trial","volume":"23","author":"Packer","year":"2021","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0550","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1568026611313020002","article-title":"NTproBNP: An important biomarker in cardiac diseases","volume":"13","author":"Panagopoulou","year":"2013","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0555","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.dsx.2018.10.006","article-title":"High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults","volume":"13","author":"Pantoja-Torres","year":"2019","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"7 Suppl","key":"10.1016\/j.pharmthera.2026.109089_bb0560","doi-asserted-by":"crossref","first-page":"3B","DOI":"10.1016\/j.amjcard.2015.01.034","article-title":"The biology of ST2: The international ST2 consensus panel","volume":"115","author":"Pascual-Figal","year":"2015","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0565","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0570","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Statistics in Medicine"},{"issue":"9402","key":"10.1016\/j.pharmthera.2026.109089_bb0575","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(03)15172-0","article-title":"CCN proteins: Multifunctional signalling regulators","volume":"363","author":"Perbal","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0580","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fendo.2015.00133","article-title":"FGF21 and cardiac physiopathology","volume":"6","author":"Planavila","year":"2015","journal-title":"Frontiers in Endocrinology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109089_bib889","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M17-0939","article-title":"Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: A guidance statement update from the american college of physicians","volume":"168","author":"Qaseem","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000549005","article-title":"The power of multiple artificial intelligence models to predict global chronic kidney disease incidence: Who leads the race?","author":"Qing","year":"2025","journal-title":"American Journal of Nephrology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0590","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2367705","article-title":"Mendelian randomization analysis revealed that albuminuria is the key factor affecting socioeconomic status in CKD patients","volume":"46","author":"Qing","year":"2024","journal-title":"Renal Failure"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0595","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/biom12091276","article-title":"Identification of unique genetic biomarkers of various subtypes of glomerulonephritis using machine learning and deep learning","volume":"12","author":"Qing","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0600","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cardfail.2023.05.018","article-title":"Association of Urine Galectin-3 with cardiorenal outcomes in patients with heart failure","volume":"30","author":"Rao","year":"2024","journal-title":"Journal of Cardiac Failure"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bb0605","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109089_bb0615","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0620","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1373\/clinchem.2008.119214","article-title":"C-reactive protein: Eighty years from discovery to emergence as a major risk marker for cardiovascular disease","volume":"55","author":"Ridker","year":"2009","journal-title":"Clinical Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0625","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, design, and baseline clinical characteristics of the Ziltivekimab cardiovascular outcomes trial: Interleukin-6 inhibition and atherosclerotic event rate reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiology"},{"issue":"10289","key":"10.1016\/j.pharmthera.2026.109089_bb0630","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with Ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bb0635","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"10118","key":"10.1016\/j.pharmthera.2026.109089_bb0640","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109089_bb0645","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 Signaling and anti-Interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circulation Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0650","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","article-title":"TGF-Beta1 and angiotensin networking in cardiac Remodeling","volume":"63","author":"Rosenkranz","year":"2004","journal-title":"Cardiovascular Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0655","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cardiores.2007.02.008","article-title":"TGF-Beta Signaling in Vascular Fibrosis","volume":"74","author":"Ruiz-Ortega","year":"2007","journal-title":"Cardiovascular Research"},{"issue":"6576","key":"10.1016\/j.pharmthera.2026.109089_bb0660","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0665","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158183","article-title":"Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress\/mitochondrial ROS\/glycolysis pathways","volume":"8","author":"Saaoud","year":"2023","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0670","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.2013070758","article-title":"Blood kidney injury Molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes","volume":"25","author":"Sabbisetti","year":"2014","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0675","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/path.3964","article-title":"Endothelial glycocalyx dysfunction in disease: Albuminuria and increased microvascular permeability","volume":"226","author":"Salmon","year":"2012","journal-title":"Journal of Pathology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0680","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: Association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0685","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dc11-1998","article-title":"Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes","volume":"35","author":"Sch\u00f6ttker","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0690","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH09-05-0297","article-title":"How much is too much? Interleukin-6 and its signalling in atherosclerosis","volume":"102","author":"Schuett","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bib877","doi-asserted-by":"crossref","first-page":"102344","DOI":"10.1016\/j.cpcardiol.2023.102344","article-title":"Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Current Problems in Cardiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109089_bb0695","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the heart failure Association of the European Society of cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"European Journal of Heart Failure"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109089_bb0700","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2337\/diabetes.51.12.3391","article-title":"Interleukin-6 induces cellular insulin resistance in hepatocytes","volume":"51","author":"Senn","year":"2002","journal-title":"Diabetes"},{"issue":"10012","key":"10.1016\/j.pharmthera.2026.109089_bib899","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(15)00391-8","article-title":"High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: A cohort study","volume":"386","author":"Shah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0705","article-title":"High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: Prospective cohort study","volume":"350","author":"Shah","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0710","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0715","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/ars.2017.7069","article-title":"Lysophospholipids and their receptors serve as conditional DAMPs and DAMP receptors in tissue oxidative and inflammatory injury","volume":"28","author":"Shao","year":"2018","journal-title":"Antioxidants & Redox Signaling"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0720","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1161\/ATVBAHA.120.314330","article-title":"Vascular endothelial cells and innate immunity","volume":"40","author":"Shao","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0725","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function","volume":"369","author":"Shlipak","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109089_bb0735","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary Prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0740","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2213-8587(13)70062-7","article-title":"Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications","volume":"1","author":"Stefan","year":"2013","journal-title":"The Lancet. Diabetes & Endocrinology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109089_bb0745","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1681\/ASN.2005121288","article-title":"Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms","volume":"17","author":"Stehouwer","year":"2006","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0750","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2215\/CJN.03670807","article-title":"Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?","volume":"3","author":"Stenvinkel","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0755","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney International"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0760","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.atherosclerosis.2006.12.018","article-title":"Ethnic differences in the ability of triglyceride levels to identify insulin resistance","volume":"196","author":"Sumner","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101696","article-title":"ROS systems are a new integrated network for sensing homeostasis and alarming stresses in organelle metabolic processes","volume":"37","author":"Sun","year":"2020","journal-title":"Redox Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109089_bb0770","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109089_bb0775","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of Low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bib896","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"7224","key":"10.1016\/j.pharmthera.2026.109089_bb0780","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.627837","article-title":"Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress","volume":"12","author":"Tirichen","year":"2021","journal-title":"Frontiers in Physiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109089_bb0790","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ki.2011.33","article-title":"A phase 1, single-dose study of Fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis","volume":"79","author":"Trachtman","year":"2011","journal-title":"Kidney International"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0795","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.hrthm.2018.12.023","article-title":"Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT study","volume":"16","author":"Truong","year":"2019","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109089_bb0800","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0805","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0810","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10741-022-10268-0","article-title":"Fibroblast growth factor 21 in heart failure","volume":"28","author":"Tucker","year":"2023","journal-title":"Heart Failure Reviews"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109089_bb0815","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJMms2004740","article-title":"Hidden in plain sight - reconsidering the use of race correction in clinical algorithms","volume":"383","author":"Vyas","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109089_bb0820","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0825","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1474-9726.2010.00629.x","article-title":"Macrophage inhibitory Cytokine-1 (MIC-1\/GDF15): A new marker of all-cause mortality","volume":"9","author":"Wiklund","year":"2010","journal-title":"Aging Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109089_bb0830","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2017.05.062","article-title":"High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants","volume":"70","author":"Willeit","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0835","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clinical Chemistry"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109089_bib879","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-Term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"Wong","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0840","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","author":"Writing Committee Members","year":"2026","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109089_bb0845","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ahj.2013.02.029","article-title":"Biological variation of Galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results","volume":"165","author":"Wu","year":"2013","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109089_bb0850","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1159\/000489623","article-title":"Soluble urokinase plasminogen activator receptor is associated with coronary artery calcification and cardiovascular disease in patients undergoing hemodialysis","volume":"43","author":"Wu","year":"2018","journal-title":"Kidney & Blood Pressure Research"},{"key":"10.1016\/j.pharmthera.2026.109089_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102771","article-title":"Early hyperlipidemia triggers metabolomic reprogramming with increased SAH, increased acetyl-CoA-cholesterol synthesis, and decreased glycolysis","volume":"64","author":"Xu","year":"2023","journal-title":"Redox Biology"},{"issue":"6941","key":"10.1016\/j.pharmthera.2026.109089_bb0860","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","article-title":"Cloning of adiponectin receptors that mediate antidiabetic metabolic effects","volume":"423","author":"Yamauchi","year":"2003","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109089_bb0865","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0870","article-title":"Gut microbiota implication in diabetic kidney disease: Mechanisms and novel therapeutic strategies","volume":"47","author":"Zhang","year":"2025","journal-title":"Renal Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109089_bb0875","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1681\/ASN.V131134","article-title":"Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease","volume":"13","author":"Zoccali","year":"2002","journal-title":"Journal of the American Society of Nephrology: JASN"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:52Z","timestamp":1786119172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":192,"alternative-id":["S0163725826001166"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109089","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109089"}}